Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCrescita Therapeutics Inc

Crescita Therapeutics Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2026-06-11T21:00:05.900009Z
Market Cap
13.77M

Momentum Score

…

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers and DuraPeel that supports the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud and Aquafolia brands; and medical aesthetics under the Pro-Derm and Alyria brands for non-invasive and minimally invasive procedures or skincare treatments. The company also distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; ART FILLER, a hyaluronic acid-based dermal filler; and MicronJet, an intradermal injection device. The company has commercialization license agreement with Cantabria Labs Inc.; and development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.40
Low
0.76
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.79
Dividend Yield
-
Revenue TTM
21.12M
Revenue Per Share
1.12
Gross Profit TTM
11.11M
Debt / Equity
0.02
ROE
-0.59%
Net Debt
-8.24M
ROCE
-6.55%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -0.08M -2.76M -1.53M 0.40M -1.01M
Net income -0.09M -2.75M -1.99M 0.86M -1.10M
Selling general administrative 10.82M 10.81M 10.12M 10.57M 8.55M
Gross profit 10.37M 9.61M 10.36M 13.18M 10.01M
Reconciled depreciation 1.50M 1.37M 1.51M 1.47M 1.38M
Ebit -1.02M -2.70M -1.46M 0.73M -0.53M
Ebitda 0.48M -1.33M 0.04M 2.20M 0.85M
Depreciation and amortization 1.50M 1.37M 1.51M 1.47M 1.38M
Operating income -1.02M -3.21M -1.96M 0.73M -0.53M
Other operating expenses 22.14M 22.80M 19.48M 23.00M 17.49M
Interest expense 0.04M 0.07M 0.09M 0.16M 0.24M
Tax provision 0.01M -0.01M 0.46M -0.46M 0.10M
Interest income 0.33M 0.34M 0.51M 0.26M 0.24M
Net interest income 0.29M 0.43M 0.42M 0.10M -0.05M
Income tax expense 0.01M -0.01M 0.46M -0.46M 0.10M
Total revenue 21.12M 19.58M 17.52M 23.52M 16.77M
Total operating expenses 11.39M 12.82M 12.32M 12.65M 10.73M
Cost of revenue 10.74M 9.97M 7.16M 10.34M 6.75M
Total other income expense net 0.94M 0.45M 0.43M -0.33M -0.48M
Net income from continuing ops -0.09M -2.75M -1.99M 0.86M -1.10M
Net income applicable to common shares - -2.75M -1.99M 0.86M -1.10M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 20.33M 21.78M 24.60M 28.48M 28.92M
Intangible assets 1.46M 1.74M 1.99M 2.87M 3.74M
Other current assets 0.31M - 0.20M 0.39M 0.62M
Total liab 4.75M 5.95M 5.78M 7.39M 8.40M
Total stockholder equity 15.58M 15.83M 18.82M 21.10M 20.53M
Other current liab 0.05M 0.05M 0.10M 5.65M 5.38M
Common stock 51.49M - 54.34M 56.30M 58.08M
Capital stock 51.49M 52.70M 54.34M 56.30M 58.08M
Retained earnings -45.44M -45.35M -42.60M -40.61M -41.48M
Other liab - - - 0.12M 0.15M
Other assets - - - 0.46M 2.18M
Cash 8.58M 9.27M 9.38M 8.24M 11.33M
Cash and equivalents - - - 8.24M 11.33M
Total current liabilities 4.72M 5.51M 4.86M 6.06M 6.72M
Net debt -8.24M - -8.13M -6.62M -8.46M
Short term debt 0.33M - 0.44M 0.41M 1.34M
Short long term debt - - - - 0.98M
Short long term debt total 0.33M - 1.25M 1.61M 2.87M
Other stockholder equity 8.41M - 5.96M 4.27M 2.77M
Property plant equipment - - - 2.31M 2.58M
Total current assets 15.72M 15.30M 18.49M 20.52M 20.09M
Long term investments 0.00M 0.31M 0.36M 0.34M 0.34M
Net tangible assets - - - 18.23M 16.79M
Short term investments - - 0.00M - -
Net receivables 2.11M 1.36M 2.77M 6.24M 3.75M
Long term debt - - - - 0.00M
Inventory 4.72M 4.05M 6.12M 5.65M 4.39M
Accounts payable 4.33M - 4.33M 5.59M 5.33M
Accumulated other comprehensive income 1.12M - 1.12M 1.13M 1.15M
Non currrent assets other - - 1.99M 2.00M 2.18M
Non current assets total 4.61M 6.47M 6.11M 7.97M 8.83M
Capital lease obligations 0.33M 0.83M 1.25M 1.61M 1.89M
Long term debt total - - - 1.21M 1.52M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -2.02M -0.13M -0.29M -0.85M
Change to liabilities - - - 0.23M 0.99M
Total cashflows from investing activities -0.97M -2.02M -0.13M -0.29M -0.85M
Net borrowings -0.52M -0.44M -0.41M -1.37M -0.35M
Total cash from financing activities -0.79M -0.86M -0.78M -1.85M -0.50M
Change to operating activities - - - 0.27M -0.27M
Net income -0.09M -2.75M -1.99M 0.86M -1.10M
Change in cash -0.70M -0.11M 1.15M -3.09M -2.95M
Begin period cash flow 9.27M 9.38M 8.24M 11.33M 14.28M
End period cash flow 8.58M 9.27M 9.38M 8.24M 11.33M
Total cash from operating activities 1.07M 2.73M 2.08M -1.02M -1.60M
Depreciation 1.50M 1.37M 1.51M 1.47M 1.38M
Other cashflows from investing activities -0.64M -0.83M 0.00M -0.06M -0.50M
Change to inventory -0.56M 2.17M -0.92M -1.78M -1.38M
Change to account receivables -0.18M 1.48M 3.54M -2.57M -1.04M
Sale purchase of stock -0.22M -0.32M -0.39M -0.43M -0.10M
Other cashflows from financing activities -0.05M -0.10M 0.02M -0.04M -0.05M
Change to netincome - - - 0.36M -0.41M
Capital expenditures 0.33M 1.19M 0.13M 0.23M 0.35M
Change in working capital 0.18M 3.91M 1.81M -3.71M -1.47M
Stock based compensation 0.07M 0.18M 0.08M 0.22M 0.27M
Other non cash items -0.53M 0.03M 0.21M 0.60M -0.77M
Free cash flow 0.74M 1.54M 1.94M -1.25M -1.94M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CURA
Curaleaf Holdings Inc.		 -0.27
2.01%		 13.13 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 -0.05
0.43%		 11.62 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 0.17
3.45%		 5.10 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 -0.25
6.02%		 3.90 - 1000.00 1.28 0.53 1.08 -2.30

Profile*

Crescita Therapeutics Inc

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers and DuraPeel that supports the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud and Aquafolia brands; and medical aesthetics under the Pro-Derm and Alyria brands for non-invasive and minimally invasive procedures or skincare treatments. The company also distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; ART FILLER, a hyaluronic acid-based dermal filler; and MicronJet, an intradermal injection device. The company has commercialization license agreement with Cantabria Labs Inc.; and development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

2805, Place Louis R Renaud, Laval, QC, Canada, H7V 0A3

800-361-0352

https://www.crescitatherapeutics.com

Name Title Year Born
Mr. Serge Verreault B.A., M.B.A. Pres & CEO NA
Mr. Jose DaRocha C.A., CPA Chief Financial Officer NA
Mr. Francois Lafortune Exec. VP & GM NA
Dominic King-Smith VP of Bus. Devel. NA
Mr. Serge Verreault B.A., M.B.A. President, CEO & Director NA
Ms. Linda Kisa Vice-President of Reporting, Corporate Affairs & Secretary NA
Ms. Linda Kisa C.A., CPA Vice-President of Reporting, Corporate Affairs & Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

THX
CAD 1.01
+9.78%
LIF
CAD 21.88
+7.84%
CIA
CAD 2.04
+6.25%
MDA
CAD 38.77
+5.76%
SXGC
CAD 8.56
+5.42%
GIL
CAD 46.32
-23.36%
NOA
CAD 12.40
-22.50%
ITH
CAD 1.95
-20.08%
TNZ
CAD 53.00
-14.24%
LSPD
CAD 14.00
-13.26%

Equity Sectors*

  • Basic Materials

    +0.02%

  • Communication Services

    +1.01%

  • Consumer Cyclical

    -1.14%

  • Consumer Defensive

    -0.06%

  • Energy

    -0.86%

  • Financial Services

    -0.32%

  • Healthcare

    -0.69%

  • Industrials

    -1.25%

  • Real Estate

    +0.16%

  • Technology

    -1.66%

  • Utilities

    -0.04%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…